- Company launches bold rebrand of Jeuveau®
(prabotulinumtoxinA-xvfs), a modern-made neurotoxin dedicated
exclusively for aesthetics
- Jeuveau® has been the fastest-growing neurotoxin in the U.S.
for two consecutive years in 2021 and 20221
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a
focus on building an aesthetic portfolio of consumer brands,
unveils fresh, new branding for its flagship neurotoxin product,
Jeuveau® (prabotulinumtoxinA-xvfs), showcased in the brand’s
marketing campaign and on Jeuveau.com. Jeuveau® stands as the
single most successful new aesthetic product launched in the United
States since 2019 and intends to continue this trajectory,
re-branding to break further away from the outdated tone, look and
feel traditionally seen in the neurotoxin market.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230807151781/en/
(Graphic: Evolus)
The new Jeuveau® imagery reflects today’s consumers, rejecting
the traditional female-focused archetype, and celebrates the
spectrum of beauty represented within the product’s growing
contingent of loyal consumers – many of whom are millennials and
younger. Inspired by this demographic, as well as the growing
number of men turning to treatments to achieve a youthful, toned,
and vibrant aesthetic, the “Jeuveau®, You See Me” marketing
campaign uses inclusive messaging to encourage consumers of all
genders to live unapologetically and embrace their beauty.
“We’re excited for the public to see the new look of Jeuveau®,
which reflects the attributes of the evolving clientele for
toxins,” said David Moatazedi, President and CEO of Evolus. “We are
immensely proud of the patient satisfaction that Jeuveau® has
delivered since 2019 – largely due to delivering excellent product
performance to the ever-changing market that is looking for a brand
that’s reflective of their needs. The rebranding of Jeuveau® is a
significant part of our commitment to doing exactly that.”
Jeuveau® has an estimated 11 percent of the current U.S.
cosmetic neurotoxin market and is available in approximately 11,000
healthcare practitioner locations around the United States. The
company recently achieved its one-millionth redemption in the
Evolus Rewards™ patient loyalty program, for which more than
one-half of enrollees are millennials or younger – signifying the
growing demand amongst this highly desirable demographic with
immense buying power.
To find the nearest Jeuveau® provider, visit
jeuveau.evolus.com/find-a-specialist/. To learn more visit
jeuveau.evolus.com.
About Jeuveau®
Dedicated exclusively for aesthetics, Jeuveau® is a modern-made
neurotoxin used for temporarily improving the appearance of
moderate to severe vertical lines between the eyebrows, known as
glabellar lines, in adults below the age of 65. The product is
approved for sale in the United States under the brand name
Jeuveau® and in Canada, Great Britain, Germany, Austria and Italy
under the brand name Nuceiva®. Approved in 2019 by the U.S. Food
and Drug Administration, Jeuveau® (prabotulinumtoxinA-xvfs) is the
first and only neurotoxin dedicated exclusively to aesthetics and
manufactured in a state-of-the-art facility using Hi-Pure™
technology. Jeuveau® is powered by Evolus’ unique technology
platform and is designed to transform the aesthetic market by
eliminating the friction points existing for customers today.
About Evolus, Inc.
Evolus (Nasdaq: EOLS) is a performance beauty company evolving
the aesthetic neurotoxin market for the next generation of beauty
consumers through its unique, customer-centric business model and
innovative digital platform. Our mission is to become a global,
multi-product aesthetics company based on our flagship product,
Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin
dedicated exclusively to aesthetics and manufactured in a
state-of-the-art facility using Hi-Pure™ technology. Evolus is
expanding its product portfolio having entered into a definitive
agreement to be the exclusive U.S. distributor of Evolysse™, a line
of five unique dermal fillers currently in late-stage development.
Visit us at www.evolus.com, and follow us on LinkedIn, Twitter,
Instagram or Facebook.
IMPORTANT SAFETY INFORMATION FOR JEUVEAU®
(prabotulinumtoxinA-xvfs)
JEUVEAU may cause serious side effects that can be life
threatening. Get medical help right away if you have any of these
problems any time (hours to weeks) after injection of
JEUVEAU:
- Problems swallowing, speaking, or breathing, due to
weakening of associated muscles, can be severe and result in loss
of life. You are at the highest risk if these problems are
pre-existing before injection. Swallowing problems may last for
several months.
- Spread of toxin effects. The effect of botulinum toxin
may affect areas away from the injection site and cause serious
symptoms including: loss of strength and all-over muscle weakness,
double vision, blurred vision and drooping eyelids, hoarseness or
change or loss of voice, trouble saying words clearly, loss of
bladder control, trouble breathing, trouble swallowing.
Do not use JEUVEAU if you: are allergic to any of the
ingredients in JEUVEAU (see Medication Guide for ingredients); had
an allergic reaction to any other botulinum toxin product such as
rimabotulinumtoxinB (MYOBLOC®), onabotulinumtoxinA (BOTOX®/BOTOX®
Cosmetic), abobotulinumtoxinA (DYSPORT®), or incobotulinumtoxinA
(XEOMIN®); have a skin infection at the planned injection site; or
are a child.
JEUVEAU dosing units are not the same as, or comparable to,
any other botulinum.
Tell your healthcare provider about all your muscle or nerve
conditions, such as ALS or Lou Gehrig’s disease, Myasthenia
gravis, or Lambert-Eaton syndrome, as you may be at increased risk
of serious side effects including difficulty swallowing and
difficulty breathing from typical doses of JEUVEAU.
Tell your healthcare provider about all your medical
conditions, including: any side effects from botulinum toxin
products, including dry eye; breathing, swallowing, bleeding, or
heart problems; plans to have surgery; weakness of forehead
muscles; drooping eyelids; have had surgery on your face; are
pregnant or breastfeeding or plan to become pregnant or breastfeed
(it is not known if JEUVEAU can harm your unborn baby or passes
into breast milk).
Tell your healthcare provider about all the medicines you
take, including prescription and over-the-counter medicines,
vitamins, and herbal supplements. Using JEUVEAU with certain other
medicines may cause serious side effects. Do not start any new
medicines until you have told your healthcare provider that you
have received JEUVEAU in the past.
Especially tell your healthcare provider if you: have
received any other botulinum toxin product in the past and the last
4 months, and exactly which product you received (such as BOTOX,
BOTOX Cosmetic, MYOBLOC, DYSPORT, or XEOMIN). JEUVEAU may cause
loss of strength or general muscle weakness, vision problems, or
dizziness within hours to weeks of treatment with JEUVEAU. If
this happens, do not drive a car, operate machinery, or do other
dangerous activities.
JEUVEAU can cause other serious side effects including:
allergic reactions such as itching, rash, red itchy welts,
wheezing, trouble breathing, asthma symptoms, or dizziness or
feeling faint. Tell your healthcare provider or get
emergency medical help right away if you develop wheezing or
trouble breathing, or if you feel dizzy or faint. Heart
problems. Irregular heartbeat and heart attack that have caused
death, have happened in some people who received botulinum toxin
products. Eye problems such as dry eye, reduced blinking,
and corneal problems. Tell your healthcare provider if you develop
eye pain or irritation, sensitivity to light, or changes in your
vision.
The most common side effects include: headache, eyelid drooping,
upper respiratory tract infection, and increased white blood cell
count.
APPROVED USE
JEUVEAU is a prescription medicine that is injected into muscles
and used in adults for a short period of time (temporary) to
improve the look of moderate to severe frown lines between the
eyebrows (glabellar lines).
The risk information provided here is not complete. For more
information about JEUVEAU, see the full Prescribing Information
including BOXED WARNING, and Medication Guide, visit evolus.com or
talk to your healthcare provider.
To report side effects associated with use of JEUVEAU, please
call 1-877-EVOLUS1/1-877-386-5871. You are encouraged to report
negative side effects of prescription drugs to the FDA. Visit
www.fda.gov/medwatch or call 1-800-FDA-1088.
Exclusively licensed and manufactured for: Evolus, Inc., 520
Newport Center Drive, Suite 1200, Newport Beach, CA 92660
1 Medical Insights US Facial Injectables Tracker, March 2023
www.miinews.com (Accessed 6/23/2023) and company estimates.
Forward-Looking Statements
This press release contains forward-looking statements as
defined under the Private Securities Litigation Reform Act of 1995
that involve risks and uncertainties, including statements about
future events, our business, financial condition, results of
operations and prospects, our industry and the regulatory
environment in which we operate. Any statements contained herein
that are not statements of historical or current facts are
forward-looking statements. In some cases, you can identify
forward-looking statements by terms such as “anticipate,”
“believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,”
“potential,” “predict,” “project,” “should,” “will,” “would” or the
negative of those terms, or other comparable terms intended to
identify statements about the future. The company’s forward-looking
statements include, but are not limited to, statements related to
market conditions and consumer demand; and the financial and other
benefits expected from the company’s branding.
The forward-looking statements included herein are based on our
current expectations, assumptions, estimates and projections, which
we believe to be reasonable, and are subject to risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by the forward-looking statements.
These risks and uncertainties, all of which are difficult or
impossible to predict accurately and many of which are beyond our
control, include, but are not limited to uncertainties associated
with our ability to comply with the terms and conditions in the
Medytox Settlement Agreements, our ability to fund our future
operations or obtain financing to fund our operations, unfavorable
global economic conditions and the impact on consumer discretionary
spending, uncertainties related to customer and consumer adoption
of Jeuveau® and Evolysse™, the efficiency and operability of our
digital platform, competition and market dynamics, our ability to
successfully launch and commercialize our products in new markets,
including the Evolysse™ dermal filler product line in the U.S., our
ability to maintain regulatory approvals of Jeuveau® or obtain
regulatory approvals for new product candidates or indications, our
reliance on Symatese to achieve regulatory approval for the
Evolysse™ dermal filler product line in the U.S., and other risks
described in our filings with the Securities and Exchange
Commission, including in the section entitled “Risk Factors” in our
Quarterly Report on Form 10-Q for the quarter ended June 30, 2023
filed with the SEC on August 2, 2023. These filings can be accessed
online at www.sec.gov. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. Except as required by law, we undertake no
obligation to update or revise any forward-looking statements to
reflect new information, changed circumstances or unanticipated
events. If we do update or revise one or more of these statements,
investors and others should not conclude that we will make
additional updates or corrections.
Jeuveau® and Nuceiva® are registered trademarks of Evolus, Inc.
Evolysse™ is a trademark of Evolus, Inc. Hi-Pure™ is a trademark of
Daewoong Pharmaceutical Co, Ltd. BOTOX® is a registered trademark
of Allergan Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230807151781/en/
Investor Contact: David K. Erickson
Vice President, Investor Relations Tel: 949-966-1798 Email:
david.erickson@evolus.com
Media Contact: Email:
media@evolus.com
Evolus (NASDAQ:EOLS)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Evolus (NASDAQ:EOLS)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024